Literature DB >> 17245351

Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop.

Angelika B Kritz1, Campbell G Nicol, Kate L Dishart, Ruth Nelson, Susan Holbeck, Dan J Von Seggern, Lorraine M Work, John H McVey, Stuart A Nicklin, Andrew H Baker.   

Abstract

Adenoviral vectors are commonly used for liver-directed gene therapy following systemic administration owing to their strong propensity for hepatocyte transduction. However, many disease applications would benefit from the delivery of adenoviruses to alternate tissues via this route. Research has thus focused on stripping the virus of native hepatic tropism in conjunction with modifying virus capsid proteins to incorporate novel tropism. Recently, the KO1S* adenovirus serotype 5 fiber mutant, devoid of both coxsackie and adenovirus receptor binding in the fiber knob domain and mutated at the putative heparan sulphate proteoglycan binding site in the fiber shaft, was shown to possess strikingly poor hepatic tropism in mice, rats, and non-human primates. Thus, it is an ideal candidate for retargeting strategies. We therefore assessed the ability of peptide-modified KO1S* fibers to retarget adenovirus. Peptide insertions were well tolerated and virions produced to high titers. However, expected retargeting at the level of transduction was not observed, despite cell-binding studies showing enhanced vector targeting at the cell surface. Cy3 labeling studies showed retarded trafficking of S*-containing fibers. Taken together, our data demonstrates that KO1S* mutant fibers are ineffective for cell retargeting strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245351     DOI: 10.1038/sj.mt.6300094

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

Review 1.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

Review 2.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

3.  Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo.

Authors:  Nelson C Di Paolo; Oleksandr Kalyuzhniy; Dmitry M Shayakhmetov
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

4.  Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Authors:  Raul Alba; Angela C Bradshaw; Alan L Parker; David Bhella; Simon N Waddington; Stuart A Nicklin; Nico van Rooijen; Jerome Custers; Jaap Goudsmit; Dan H Barouch; John H McVey; Andrew H Baker
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

5.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

6.  Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells.

Authors:  Mari I Jonsson; Annasara E Lenman; Lars Frängsmyr; Cecilia Nyberg; Mohamed Abdullahi; Niklas Arnberg
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

7.  With a little help from my f(X)riends!: the basis of Ad5-mediated transduction of the liver revealed.

Authors:  Pedro R Lowenstein
Journal:  Mol Ther       Date:  2008-06       Impact factor: 11.454

8.  DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice.

Authors:  Tomoya Terashima; Kazuhiro Oka; Angelika B Kritz; Hideto Kojima; Andrew H Baker; Lawrence Chan
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.

Authors:  Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.